Intercept Pharmaceuticals, Inc.
GPTKB entity
Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
Alfasigma S.p.A.
|
| gptkbp:acquisitionYear |
2023
|
| gptkbp:CEO |
gptkb:Jerry_Durso
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
liver diseases
|
| gptkbp:founded |
2002
|
| gptkbp:founder |
gptkb:Mark_Pruzanski
|
| gptkbp:headquarters_location |
gptkb:Morristown,_New_Jersey,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Intercept Pharmaceuticals, Inc.
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableProduct |
gptkb:obeticholic_acid
gptkb:Ocaliva |
| gptkbp:numberOfEmployees |
approximately 400 (2022)
|
| gptkbp:specializesIn |
gptkb:primary_biliary_cholangitis_(PBC)
treatments for nonalcoholic steatohepatitis (NASH) |
| gptkbp:tradedOn |
gptkb:NASDAQ:_ICPT
|
| gptkbp:website |
https://www.interceptpharma.com/
|
| gptkbp:bfsParent |
gptkb:NASDAQ:_ICPT
|
| gptkbp:bfsLayer |
8
|